Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL
Public ClinicalTrials.gov record NCT01994382. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2a Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell or T-Cell Non-Hodgkin Lymphoma (NHL)
Study identification
- NCT ID
- NCT01994382
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Enrollment
- 260 participants
Conditions and interventions
Conditions
Interventions
- Cerdulatinib Drug
- Rituximab Biological
Drug · Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 29, 2013
- Primary completion
- Dec 14, 2020
- Completion
- Dec 14, 2020
- Last update posted
- Apr 4, 2022
2013 – 2020
United States locations
- U.S. sites
- 23
- U.S. states
- 19
- U.S. cities
- 23
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Huntsville | Alabama | 35805 | — |
| Not listed | Gilbert | Arizona | 85234 | — |
| Not listed | Los Angeles | California | 90095 | — |
| Not listed | Palo Alto | California | 94304 | — |
| Not listed | Washington D.C. | District of Columbia | 20007 | — |
| Not listed | Gainesville | Florida | 32608 | — |
| Not listed | Sarasota | Florida | 34232 | — |
| Not listed | Lawrenceville | Georgia | 30046 | — |
| Not listed | Chicago | Illinois | 60637 | — |
| Not listed | Louisville | Kentucky | 40207 | — |
| Not listed | Baltimore | Maryland | 21229 | — |
| Not listed | Ann Arbor | Michigan | 48109 | — |
| Not listed | Hattiesburg | Mississippi | 39402 | — |
| Not listed | Hackensack | New Jersey | 07601 | — |
| Not listed | Morristown | New Jersey | 07960 | — |
| Not listed | New York | New York | 10021 | — |
| Not listed | Philadelphia | Pennsylvania | 19104 | — |
| Not listed | Charleston | South Carolina | 29412 | — |
| Not listed | Arlington | Texas | 76012 | — |
| Not listed | Lubbock | Texas | 79410 | — |
| Not listed | Richmond | Virginia | 23226 | — |
| Not listed | Seattle | Washington | 98109 | — |
| Not listed | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01994382, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 4, 2022 · Synced May 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01994382 live on ClinicalTrials.gov.